Core Viewpoint - Shattuck Labs, Inc. is advancing its lead product candidate, SL-325, a first-in-class DR3 blocking antibody, with ongoing clinical trials and promising financial results, indicating a strong potential for growth in the biotechnology sector focused on inflammatory and immune-mediated diseases [1][2][3]. Financial Results - As of December 31, 2025, Shattuck reported cash and cash equivalents of approximately $78.1 million, an increase from $73.0 million in 2024 [10]. - Research and Development (R&D) expenses for Q4 2025 were $9.1 million, down from $15.4 million in Q4 2024, and total R&D expenses for the year were $35.3 million compared to $67.2 million in 2024 [10]. - General and Administrative (G&A) expenses for Q4 2025 were $4.3 million, slightly up from $4.2 million in Q4 2024, while total G&A expenses for the year decreased to $17.2 million from $19.1 million in 2024 [10]. - The net loss for Q4 2025 was $12.6 million, or $0.12 per share, compared to a net loss of $18.7 million, or $0.37 per share, in Q4 2024 [10]. Clinical Development - SL-325 is currently in a Phase 1 clinical trial, with data expected to be released in Q2 2026, and a Phase 2 trial in Crohn's disease anticipated to start in Q3 2026 [5][6]. - The Phase 1 trial aims to evaluate safety, tolerability, immunogenicity, and pharmacokinetics, with full enrollment expected to be completed in Q2 2026 [6]. - Shattuck is also developing multiple DR3-based bispecific antibodies, with the lead bispecific antibody entering IND-enabling activities [6]. Management Updates - Michael Choi, M.D., was appointed as Vice President of Clinical Development in November 2025, bringing significant experience in inflammatory bowel disease programs [3]. Upcoming Events - Shattuck plans to participate in several investor conferences, including the Leerink Global Healthcare Conference from March 8-11, 2026, where the CEO will present [11].

Summary of Shattuck Labs FY Conference Call Company Overview - **Company**: Shattuck Labs (NasdaqGS:STTK) - **Focus**: Development of DR3 blocking antibodies, specifically targeting the TL1A pathway in inflammatory bowel disease (IBD) [1][2] Core Points and Arguments - **Mechanism of Action**: - DR3 is the receptor for TL1A, and blocking this receptor may provide superior efficacy compared to TL1A blocking antibodies due to its stability and lower immunogenicity [2][4] - TL1A blocking antibodies have a high incidence of anti-drug antibodies (ADA), with over 64% of patients developing ADA, which can lead to reduced efficacy [5][11] - **Clinical Development**: - Shattuck Labs is currently in Phase I clinical trials for their human DR3 blocking antibody, SL-325, and expects to share data in Q2 [6][10] - A Phase 2b randomized controlled study in Crohn's disease is planned to start in Q3, with a target enrollment of 170-180 patients [26][28] - **Efficacy Expectations**: - The company aims for a 100% blockade of TL1A signaling, which is expected to lead to improved clinical outcomes compared to existing therapies [13][18] - Previous studies indicate that ADA levels significantly impact the efficacy of TL1A antibodies, with a 50% drop in efficacy observed as ADA titers increase [18][19] - **Safety Profile**: - The engineered SL-325 antibody is designed to minimize off-target effects and does not cause receptor-mediated endocytosis of DR3, reducing the risk of adverse events [8][9][10] - Non-human primate studies showed no evidence of T cell proliferation or adverse effects, supporting the safety profile expected in humans [25] Additional Important Content - **Competitive Landscape**: - The competitive landscape includes various companies developing TL1A blocking antibodies, while Shattuck Labs is one of the few focusing on DR3 blocking antibodies [6] - **Future Directions**: - Plans to develop bispecific antibodies targeting DR3 are underway, with expectations to share details later this year [34] - The company is considering the potential for life cycle management and indication splitting for SL-425, a half-life extended version of SL-325 [32] - **Market Considerations**: - The company believes that demonstrating efficacy in Crohn's disease will also translate to ulcerative colitis, given the mechanistic similarities and current market dynamics [27] - **Regulatory and Development Strategy**: - The Phase 2b study will assess both high and low doses against a placebo, with a focus on achieving a minimum of 25% improvement in endoscopic response rates [28][29] This summary encapsulates the key points discussed during the conference call, highlighting Shattuck Labs' strategic focus on DR3 blocking antibodies and their anticipated impact on the treatment of inflammatory bowel disease.

Summary of Shattuck Labs FY Conference Call Company Overview - **Company**: Shattuck Labs (NasdaqGS:STTK) - **Event**: FY Conference on December 02, 2025 Industry Focus - **Industry**: Biotechnology, specifically focusing on antibody therapies for inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn's disease Key Points and Arguments 1. **Lead Antibody**: The primary focus is on SL325, a DR3 blocking antibody, with a half-life extended version called SL425 mentioned but not discussed in detail [2][19] 2. **Biological Mechanism**: The presentation emphasizes the TL1A-DR3 axis, where TL1A is the ligand and DR3 is the receptor. The company believes that targeting DR3 may offer advantages over TL1A blocking antibodies, particularly in terms of safety and efficacy [3][4] 3. **Efficacy Comparison**: Emerging data suggests that TL1A blocking antibodies show efficacy similar to JAK inhibitors but with fewer toxicities. Shattuck Labs posits that DR3 blocking could provide more durable inhibition and a better safety profile [3][11] 4. **Immunogenicity Concerns**: TL1A antibodies have shown high rates of anti-drug antibodies (ADA), leading to accelerated clearance and reduced efficacy. In contrast, DR3 targeting is expected to minimize immune complex formation, potentially improving the immunogenicity profile [11][12] 5. **Preclinical Data**: SL325 has demonstrated high affinity (1-picomolar binding) and specificity, with preclinical studies indicating no residual agonism and effective inhibition of TL1A-mediated cytokine production [5][14] 6. **Phase 1 Study**: The company is currently conducting a Phase 1 study in healthy volunteers, aiming to assess safety, receptor occupancy, and immunogenicity. Results are expected in the first half of 2026 [17][18] 7. **Funding and Future Trials**: Shattuck Labs is funded through Phase 2 trials, with cash reserves projected to last until 2029 due to recent financing [19] Additional Important Information - **Competitive Landscape**: The company acknowledges a competitive landscape for both TL1A and DR3 targeting but believes it has a unique position with its DR3 blocking approach [18] - **Dosing Interval**: While the dosing interval has not been disclosed, the target for maintenance is approximately every 8 weeks, pending Phase 1 data [19]

Core Viewpoint - Shattuck Labs, Inc. has initiated a Phase 1 clinical trial for its lead product candidate SL-325, a DR3 blocking antibody, and has reported financial results for Q3 2025, highlighting its strong capital position to advance clinical development [1][2][3]. Business Highlights - SL-325 is the first DR3 blocking antibody to enter clinical development, with the Phase 1 trial proceeding as planned [2]. - The company closed a private placement of approximately $103 million in August 2025, which is expected to fund operations into 2029 and support multiple clinical milestones for SL-325 [3][6]. - Recent appointments to the Board of Directors include Dan Baker, M.D., and Mona Ashiya, Ph.D., enhancing the company's leadership [4][6]. Clinical Development - The Phase 1 trial for SL-325 began with the first participants dosed in Q3 2025, focusing on safety, tolerability, immunogenicity, and pharmacokinetics [7]. - Enrollment for the single-ascending dose (SAD) and multiple-ascending dose (MAD) portions is expected to be completed by Q2 2026, with initial results anticipated by the same timeframe [7]. - The company is also developing preclinical DR3-based bispecific antibodies aimed at treating inflammatory bowel disease (IBD) [7]. Financial Results - As of September 30, 2025, cash and cash equivalents were approximately $86.1 million, down from $90.1 million a year earlier [10][14]. - Research and Development (R&D) expenses for Q3 2025 were $7.6 million, a decrease from $16.3 million in Q3 2024 [14]. - The net loss for Q3 2025 was $10.1 million, or $0.14 per share, compared to a net loss of $16.6 million, or $0.33 per share, in the same quarter of the previous year [14][21].